Analysts Set Sanofi (NASDAQ:SNY) Price Target at $60.00

Sanofi (NASDAQ:SNY) has been assigned a consensus rating of “Buy” from the five ratings firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $62.50.

SNY has been the topic of several research reports. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, The Goldman Sachs Group assumed coverage on Sanofi in a report on Friday. They set a “neutral” rating and a $65.00 price objective on the stock.

Sanofi Stock Performance

Shares of Sanofi stock opened at $56.90 on Friday. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The company has a market cap of $144.40 billion, a PE ratio of 22.85, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The company has a 50 day moving average of $54.55 and a 200-day moving average of $52.85. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, equities research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sanofi

Several hedge funds and other institutional investors have recently bought and sold shares of SNY. Invesco Ltd. raised its position in shares of Sanofi by 3.5% in the 4th quarter. Invesco Ltd. now owns 12,059,283 shares of the company’s stock worth $581,619,000 after acquiring an additional 408,752 shares in the last quarter. Bank of America Corp DE grew its stake in Sanofi by 3.8% during the fourth quarter. Bank of America Corp DE now owns 12,017,140 shares of the company’s stock worth $579,587,000 after purchasing an additional 441,637 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company’s stock worth $522,991,000 after purchasing an additional 5,091,304 shares in the last quarter. Boston Partners lifted its stake in Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company’s stock valued at $260,607,000 after buying an additional 2,501,073 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in shares of Sanofi by 10.8% during the 4th quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company’s stock worth $182,164,000 after buying an additional 369,530 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.